LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

Company Overview

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $9.69 to $9.72
• 50-Day Range: $8.60 to $10.10
• 52-Week Range: $7.05 to $10.35
• Volume: 3,827 shs
• Average Volume: 134,271 shs
• Market Capitalization: $443.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LogicBio Therapeutics Stock Analysis - MarketRank™

LogicBio Therapeutics scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for LogicBio Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of LogicBio Therapeutics is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LogicBio Therapeutics is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LogicBio Therapeutics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.93% of the float of LogicBio Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LogicBio Therapeutics has a short interest ratio ("days to cover") of 7.74.

Change versus previous month

Short interest in LogicBio Therapeutics has recently decreased by 4.10%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LogicBio Therapeutics does not currently pay a dividend.

Dividend Growth

LogicBio Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for LOGC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

2 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/09/2025
• Today: 8/04/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:LOGC
• CIK: 1664106
• Web: www.logicbio.com
• Phone: (617) 245-0399
• Fax: N/A
• Employees: 62
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29 million
• Net Margins: N/A
• Pretax Margin: -156.79%
• Return on Equity: -1.73%
• Return on Assets: -1.22%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 1.67
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $43 million
• Price / Sales: 10.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.95 per share
• Price / Book: 1.96

Miscellaneous

• Outstanding Shares: 45,730,000
• Free Float: 26,309,000
• Market Cap: $443.58 million
• Optionable: No Data
• Beta: 2.02